Loading...
Please wait, while we are loading the content...
The management of patients with metastatic prostate cancer during the COVID-19 pandemic.
| Content Provider | Europe PMC |
|---|---|
| Author | Assi, Tarek Ibrahim, Nathalie K Abboud, Rita-Maria Kattan, Clarisse Rassy, Elie Nemr, Elie Kattan, Joseph |
| Copyright Year | 2020 |
| Abstract | During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7426764&blobtype=pdf |
| Page Count | 7 |
| ISSN | 14796694 |
| Volume Number | 16 |
| DOI | 10.2217/fon-2020-0361 |
| PubMed Central reference number | PMC7426764 |
| Issue Number | 20 |
| PubMed reference number | 32412310 |
| Journal | Future Oncology [Future Oncol] |
| e-ISSN | 17448301 |
| Language | English |
| Publisher | Future Medicine Ltd |
| Publisher Date | 2020-05-15 |
| Publisher Place | London, UK |
| Access Restriction | Open |
| Rights License | This work is licensed under the Creative Commons Attribution 4.0 License © 2020 Future Medicine Ltd |
| Subject Keyword | castrate resistant coronavirus COVID-19 hormone sensitive immunosuppression metastatic prostate cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |
